Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
AssigneeH. Lundbeck A/S
InventorsConnie Sanchez Morillo, Gennady N. Smagin
Life of this patent
Estimating the term…
Abstract
The present invention relates to an opioid antagonist with κ-activity for use in treatment of depressive disorder with melancholic features. The invention further relates to the combination of an opioid antagonist with κ-activity and vortioxetine for use in treatment of depressive disorder with melancholic features. The invention also relates to pharmaceutical compositions comprising an opioid antagonist with κ-activity and vortioxetine.
Claims14
A method of treating a patient having depressive disorder with melancholic features, comprising administering a therapeutically effective amount of an opioid antagonist with κ-activity to the patient, wherein said administered opioid antagonist is nalmefene, and wherein said method further comprises administering a therapeutically effective amount of vortioxetine to the patient.
A pharmaceutical composition comprising an opioid antagonist with κ-activity and vortioxetine together with a pharmaceutically acceptable excipient, wherein said opioid antagonist is nalmefene.
Dependencies are inferred from the claim text.